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Abstract Anti-citrullinatedpeptideantibodies(ACPA)and
the rheumatoid factor (RF) are well-established serological
markers for rheumatoid arthritis (RA). ACPA are very useful
in the diagnosis of RA, especially at the early stages of the
disease when ACPA have a greater diagnostic value than RF.
The aim of the study was to assess the inﬂuence of inﬂiximab
treatmentonRFIgMandACPAserumlevelsandRAactivity
during 6 months of treatment. Thirty-two patients with
refractory RA were treated with inﬂiximab during a 6-month
period. At baseline, 3 and 6 months of treatment the patients
wereexaminedforthenumberswollenandtenderjointsoutof
28(SJC,TJC)andthevisualanaloguescaleofarthritisactivity
accordingtothepatient(VAS).Serumsamplesweretestedfor
erythrocyte sedimentation rate (ESR), C-reactive protein
level (CRP), ACPA and RF IgM. The disease activity score
(DAS-28) parameter was also calculated at the same time.
During the course of our study, we observed statistically sig-
niﬁcantimprovementinESR,CRP, TJC,SJC,VAS DAS-28,
andRFIgMafter3and6 monthsofinﬂiximabtreatmentwhen
compared to the baseline, whereas the ACPA level remained
unchanged after 3 and 6 months of treatment (P = 0.96 and
P = 0.85).ThechangesintheACPAlevelarenotafactorfor
evaluation of successful inﬂiximab treatment but the changes
in RF IgM are. According to different behavior of these anti-
bodiesduringinﬂiximabtreatment,wesuggestthattherolesof
ACPA and RF in the pathogenesis of RA are different.
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic inﬂam-
matory disease that afﬂicts the synovium of diarthrodial
joints and is characterized by synovial inﬂammation lead-
ing to cartilage destruction, bone erosion and eventually to
disability of the patient.
The etiology of RA still remains elusive although the
disease is known to be of autoimmune origin. Supportive
ﬁndings for this theory are the presence of IgG autoanti-
bodies, such as the rheumatoid factor (RF), and anti-
citrullinated peptide antibodies (ACPA). The process
called citrullination relies upon posttranslational deimina-
tion of arginine and its conversion to a new, non-standard
aminoacid—citrulline. Arginine is a positively charged
aminoacid but citrulline is neutral.
The production of ACPA is strongly associated with
MHC class II molecules that contain a motif known as the
shared epitope, such as HLA-DRB1*0401, and subsequent
CD4 cells activation [1].
ACPA are up to 98.5% speciﬁc and 70% sensitive to
rheumatoid arthritis (RA) [2–4], and may be detected very
early in the disease, even prior to the onset of clinical
symptoms [5, 6]. There are also data proving that the
presence of ACPA has a prognostic value and is highly pre-
dictiveofmoresevereradiologicdamagecomparedtoACPA
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theseantibodies.Moreover,fewpatientswithotherrheumatic
diseases are positive, with some exceptions of other condi-
tions with clinical similarities to RA [8].
The new biologic methods of treatment of RA using
anti-TNF agents (i.e., inﬂiximab) are effective in patients
with refractory RA. The majority of inﬂiximab-treated
patients present improvement in clinical symptoms and
signs of RA and laboratory markers of inﬂammation, such
as C-reactive protein (CRP) [9–11]. On the other hand, up
to 25% of treated patients have a poor response to this kind
of treatment [12]. There are no reliable factors to predict
the response to treatment. The rheumatoid factor (RF)
usually decreases during successful treatment [13–15].
Data concerning inﬂuence of inﬂiximab treatment on the
serum level of aCCP antibodies are contrary [14, 16].
A signiﬁcant number of patients with RA (up to 40%)
experience early development of joint destruction [17].
Quick and successful treatment of this group of patients is
very important, so is early separating of unresponsive
patients.
The aim of the study was to assess the inﬂuence of
inﬂiximab treatment on RF IgM and ACPA serum levels
and RA activity during 6 months of treatment.
Materials and methods
Thirty-two patients with refractory RA were enrolled in the
study (28 females and seven males, mean 45.4 years, range
from 19 to 60). All of them were RF positive and 25 out of
32 (78%) were aCCP positive. The patients were treated at
the Department of Rheumatology and Connective Tissue
Diseases, Medical University of Lublin.
All patients had a history of failed treatment with at least
one disease modifying antirheumatic drug (DMARD).
Patients were allowed to continue DMARDs, steroids, and
non-steroidal anti-inﬂammatory drugs before and during
inﬂiximab treatment. None of the patients had an infectious
disease, active or latent tuberculosis, neoplastic disease,
heart failure, cytopenia, or a demyelinating disorder.
The patients received 3 mg/kg inﬂiximab intravenously
at weeks 0, 2, 6, and every 8 weeks thereafter. Metho-
trexate was given in a dose of 10–20 mg weekly. In
addition to methotrexate, chloroquine (250 mg daily) and
steroids (maximum daily dose 10 mg of oral prednisone or
equivalent) were also permitted.
Written informed consent was obtained from all
patients, and the study was approved by the Bioethics
Committee of the University of Lublin.
Blood serum samples were collected from all patients at
baseline and after 3 and 6 months of anti-TNF treatment.
The sera were stored at -70C until further analysis.
The patients were examined clinically at baseline and
after 3 and 6 months of the study by the same physician
during each visit for inﬂiximab infusion. Clinical evalua-
tion included the number of tender (TJC) and swollen
(SJC) joints, visual analogue scale of arthritis activity
according to the patient (VAS), erythrocyte sedimentation
rate (ESR), and C-reactive protein level (CRP). The DAS-28
parameter was used to evaluate clinical activity and the
response to treatment.
ACPA were tested using a third-generation commer-
cially available enzyme-linked immunoabsorbent assay—
ELISA, Quanta Life CCP IgG Elisa of Inova, US and RF
was determined with ELISA IgM Kit, Euroimmun,
Germany. All the serum samples of patients with RA were
analyzed in a single session according to the manufac-
turer’s instructions. ACPA levels were measured in arbi-
trary units per milliliter and were considered to be positive
at a cutoff value of C20 U/ml. The RF IgM results were
presented in relative units per milliliter (RU/ml) with a
cutoff value of 20 RU/ml for a positive result. The CRP
level and ESR were measured each time on the day of
inﬂiximab infusion.
Statistical analysis was performed using Statistica 7.0
PL software. Differences between groups were analyzed
using Mann–Whitney U test. A P value less than 0.05 was
considered statistically signiﬁcant.
Results
During the course of our study, we observed statistically
signiﬁcant improvement in clinical parameters of RA
activity. We noted a signiﬁcant decrease in ESR, CRP,
TJC, SJC, VAS, DAS-28, and RF IgM after 3 and
6 months of inﬂiximab treatment when compared to the
baseline. The exact data are presented in Table 1.
The ACPA levels did not exhibit a signiﬁcant reduction
after 3 and 6 months of inﬂiximab treatment (Fig. 1).
The mean baseline level value of ACPA was
716.97 ± 663.76, it changed to 728 ± 678.27 after
3 months (P = 0.96) and to 684.36 ± 647.8 after
6 months (P = 0.85) of inﬂiximab treatment.
There were no cases of ACPA normalization during this
treatment (lowering below 20 U/ml).
A signiﬁcant reduction in RF IgM was observed after 3
and 6 months of treatment, with P = 0.035 and P = 0.005,
respectively (Fig. 2).
Discussion
The improvement in clinical and laboratory tests during
anti-TNF treatment is now beyond discussion [18–20].
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diagnosis of RA, especially at the early stages of the dis-
ease when ACPA have a greater diagnostic value than RF
[3].
In our study, the level of ACPA did not signiﬁcantly
change after 3- and 6-month periods of inﬂiximab treat-
ment. The same constellation of results was also found in
previous studies [13, 21]. Other researchers reported a
signiﬁcant reduction in the serum level of ACPA after
treatment with adalimumab [22], etanercept and inﬂiximab
[23, 24]. In contrast to these ﬁndings, De Rycke et al.
observed no signiﬁcant inﬂuence of successful inﬂiximab
treatment on the ACPA level after 30 weeks of observation
but an evident and signiﬁcant decrease in RF IgM during
such a treatment [16]. Similar data were lately reported by
Bruns et al. [25].
The posttranslational conversion of arginine, called
citrullination, leads to changes in the modiﬁed proteins
containing citrulline, leading to changes in the molecular
mass and lack of positive charge. The physiological role of
this process remains unknown, but it has been suggested
that citrullination may play a certain role in disintegration
of cells and proteins by apoptosis [26] and regulation of
transcription [27].
The presence of ACPA is detectable years before the ﬁrst
symptomsofRAandseemstobeverystableduringthecourse
of the disease without signiﬁcant changes from ACPA nega-
tive to positive or inversely [28]. According to these authors,
ACPA is a stable phenotype during the course of RA.
Van Gaalen et al. have shown an association between HLA
DRB1genesandthepresenceofACPA.Moreover,ithasbeen
observed that only shared epitope-positive patients produce
ACPA [29]. Similar data were found by Auger et al. [30].
According to Johanson et al. [31], there is a very strong
positive correlation between PTPN22 gene and ACPA pro-
duction. The above genetic connections of ACPA and their
presence at the early stages of RA or even many years before
thediseasecouldexplainwhytheACPAlevelissostableand
did not change during our observation. The genetic connec-
tions ofACPA are knownbut theyneedfurther investigation.
AsreportedbyPotteretal.[32],thereisanegativecorrelation
between the response to anti-TNF treatment and the absence
ofRForACPA.Itcontrast,theydidnotﬁndacorrelationwith
SE or PTPN22 presence in the same group of patients [32].
De Rycke et al. [16] have suggested that RF and ACPA
are two different and independent autoantibody systems in
RA. These two factors may provide different but comple-
mentary information on RA [16].
Table 1 The results of ACPA,
RF IgM, ESR, CRP, DAS-28,
TJC, SJC, VAS at baseline, after
3 and 6 months of inﬂiximab
treatment of patients with RA
# P\0.05 Baseline to
3 months, * P\0.05 Baseline
to 6 months
Baseline 3 months 6 months
ACPA (U/ml) 716.97 ± 663.76 728.73 ± 678.27 684.36 ± 647.8
RF IgM (RU/ml) 1,657.31 ± 627.58 1,298.87 ± 574.47# 1,102.09 ± 578.23*
ESR (mm/h) 44.56 ± 29.86 20.96 ± 15.5# 19.92 ± 16.6*
CRP (mg/dl) 38.85 ± 45.76 12.93 ± 17.15# 11.00 ± 13.13*
DAS-28 6.02 ± 0.81 3.87 ± 1.2# 3.69 ± 1.29*
TJC (0–28) 11.44 ± 5.44 4.32 ± 4.35# 4.16 ± 4.72*
SJC (0–28) 9.52 ± 5.70 4.28 ± 3.24# 3.92 ± 3.92*
VAS (mm) 57.84 ± 13.81 28.88 ± 22.81# 22.92 ± 17.9*
Fig. 1 ACPA levels at baseline and after 3 and 6 months of
inﬂiximab treatment of patients with RA
Fig. 2 RF IgM level at baseline and after 3 and 6 months of
inﬂiximab treatment of patients with RA
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changes concerning ACPA and RF IgM during successful
inﬂiximab treatment, we concluded that their roles in the
pathogenesis of RA seem to be different. ACPA seems to
be more stable and genetically dependent. The impact of
short-term inﬂiximab treatment on TNF-a does not inﬂu-
ence the expression of genes involved in ACPA
production.
Conclusion
Six months of anti-TNF therapy do not inﬂuence ACPA
level, contrary to a signiﬁcant decrease in RF IgM
concentration. According to different behavior of these
antibodies during inﬂiximab treatment, we suggest that the
roles of ACPA and RF IgM in the pathogenesis of RA are
different. Further studies are needed to establish the exact
role of ACPA and RF IgM in the pathogenesis of RA.
Serial ACPA measurements should not be used as an early
predictive factor of a good response in inﬂiximab treatment
of RA.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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